Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

ress releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding ViroPharma's supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. There can be no assurance that the complete data from the open label study will demonstrate that Cinryze successfully treats all types of acute hereditary angioedema (HAE) attacks and may not be predictive of the results of any future testing. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a co
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 - ... Trendlines Agtech , announced it has signed ... leading agricultural thermoplastics applications companies. ... technology combines nanocrystalline cellulose (NCC), a biodegradable, transparent ... nanoparticles to produce highly improved polymeric films. Used ...
(Date:7/23/2014)... 23, 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced that the underwriters of its ... to purchase an additional 420,000 shares of common ... per share, less underwriting discounts and commissions, in ... of 2,800,000 shares of common stock, bringing the ...
(Date:7/23/2014)... , July 23, 2014 ... SHPG ), the global specialty biopharmaceutical company, and ... announced a worldwide licensing and collaboration agreement for ... the potential treatment of both the central nervous ... Hunter syndrome (MPS II). This collaboration strengthens Shire,s ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Sofinnova Raises $500 Million Biotech Venture Fund 2
... physics of the perfect pizza toss and will use ... thinner that a human hair. , Mr Daniel (Kuang-Chen) ... Friend and Senior Lecturer Leslie Yeo, videotaped a professional ... Research Laboratory, then calculated how best to describe the ...
... WAYNE, Pa., April 27 Encorium Group, Inc. ... full-service multinational contract research organization (CRO) that provides design, ... registries to many of the world,s leading pharmaceutical companies, ... new business contracts, consisting of both new business contracts ...
... ", or "the Company") (OTC Bulletin Board: SNBP) is ... seven key patents from Company CEO Dr. Lequn Huang ... enhance Sinobiopharma,s ability to execute on its mission of ... for the following:, , ...
Cached Biology Technology:Pizza tossing art unlocks secrets of tiny motors 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 2Encorium Group Signs Approximately $2.0 Million of New Business Contracts 3Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:7/23/2014)... health risk warning for Yellowknife and surrounding area because ... fires. In the image taken by the Aqua ... patterns. Fire is an obvious health hazard, but ... so obvious and its effects are insidious. , The ... crop, structure, tires, waste or wood burning) is a ...
(Date:7/23/2014)... , , , , ... , , , , ... extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost ...
(Date:7/23/2014)... 23, 2014 Migratory songbirds are disappearing, and though ... change, loss of habitat, acid rain and light pollution, ... where do these birds go once they leave their ... along the way? , To answer this question, a ... the first ever migratory connectivity map produced for a ...
Breaking Biology News(10 mins):Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2
... clinical trial, a new drug that selectively blocks ... acute kidney transplant rejection as cyclosporine, the standard ... experimental drug, a co-stimulatory blocker called belatacept (LEA29Y), ... of the toxic side effects associated with standard ...
... and chimpanzees both pass on "traditions" to other members ... feeding behaviour. The findings add to evidence that cultural ... involved killerwhales at Marineland in Niagara Falls in Ontario, ... to catch birds, and passed the strategy on to ...
... mast cells, known to play a central role in ... that can kill these cells by programming them to ... move researchers another step closer to understanding the life ... new treatments for allergy and inflammatory responses in arthritis, ...
Cached Biology News:New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4More animals join the learning circle 2Climate model links higher temperatures to prehistoric extinction 2
... DNA Polymerase is a thermostable recombinant DNA ... primer extension and other molecular biology applications. ... provides easy and quick identification of reactions ... confirmation of complete mixing. The inert dye ...
... PCR (MSP) is a new technology ... methylation utilizing small amounts of DNA ... bisulfite reaction to modify the DNA, ... primers designed to distinguish methylated from ...
... m7G(5')ppp(5')G (Cap Analog) is used for ... in in vitro transcription reactions. Substitution of ... the GTP in an in vitro transcription ... cap structure into a large fraction of ...
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. The iEMS ... a one-cabinet model, allowing the ...
Biology Products: